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Introduction: Patients with hepatitis C virus (HCV) infection and chronic kidney disease (CKD) are a high-
priority population for treatment.
Methods: We performed a post hoc pooled efficacy and safety analysis that included HCV genotype
1–infected patients with compensated liver disease and CKD stages 1 to 3 who received the all-oral 3–
direct-acting antiviral regimen of ombitasvir, paritaprevir, ritonavir, and dasabuvir  ribavirin (OBV/PTV/
r þ DSV  RBV) in 11 phase 3 clinical trials. Sustained virologic response rates at posttreatment week 12
(SVR12) and treatment-related adverse events (AEs), serious AEs, and renal-associated AEs are reported.
Mean changes from baseline in serum creatinine and estimated glomerular filtration rate (eGFR) were
calculated to assess changes in renal function. Factors associated with improved eGFR were assessed by
stepwise logistic regression analysis of data from 7 trials in which baseline urinalysis was collected.
Results: SVR12 rates in patients with stage 1, 2, and 3 CKD were 97% (439/453), 98% (536/547), and 97%
(32/33), respectively, with OBV/PTV/r þ DSV; and, 96% (1172/1221), 96% (1208/1254), and 93% (55/59),
respectively, with OBV/PTV/r þ DSV þ RBV. Overall rates of serious AEs and renal AEs were 3% (95/3567)
and 2% (56/3567), respectively. Factors associated with an eGFR increase of $10 ml/min per 1.73 m2 were
baseline proteinuria, body mass index, nonblack race, and history of diabetes.
Conclusion: OBV/PTV/r þ DSV  RBV achieved high SVR rates and was generally well tolerated irre-
spective of CKD stage.
Kidney Int Rep (2019) 4, 245–256; https://doi.org/10.1016/j.ekir.2018.10.005
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P atients with HCV infection have an increased riskof developing CKD.1–4 Moreover, patients with
CKD and HCV have a greater risk of CKD progression
and end-stage renal disease (ESRD),3,5 and the preva-
lence of HCV infection is higher in patients who
require hemodialysis than in the general population.6,7
Furthermore, HCV infection is associated with reduced
graft survival after renal transplantation.7 Therefore, it
is critical that patients with HCV and CKD receive
treatment for HCV.
Contemporary HCV treatment guidelines recommend
that patients with extrahepatic manifestations of HCV
infection be considered a priority for treatment owing to
increased risk of disease progression.8,9 However, few
data are available on the safety and efficacy of direct-
acting antiviral (DAA) regimens in patients with CKD.
Components of the 3-DAA regimen of ombitasvir,
paritaprevir with the pharmacokinetic enhancer rito-
navir, and dasabuvir (OBV/PTV/r þ DSV) are primarily
metabolized by the liver with minimal renal elimina-
tion, with no dose adjustment required in patients with
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CLINICAL RESEARCH
mild to severe renal impairment.8,9 However, patients
with HCV genotype (GT) 1a infection require treatment
with ribavirin (RBV), which is renally excreted and
requires dose reduction in patients with a creatinine
clearance (CrCl) #50 ml/min.10 OBV/PTV/r þ DSV 
RBV is recommended in guidelines for treatment of
HCV in patients with CrCl <30 ml/min or ESRD
requiring hemodialysis.8,9
To better define the safety and efficacy profile of
OBV/PTV/r þ DSV  RBV, we conducted a post hoc
pooled analysis of OBV/PTV/r þ DSV in HCV GT1-
infected patients with CKD stages 1 to 3 across 11
phase 3 studies.
METHODS
Study Design
This is a post hoc pooled analysis of the efficacy and
safety of the all-oral 3-DAA regimen of OBV/PTV/r þ
DSV  RBV among patients with CKD, as determined
by baseline eGFR using the Modification of Diet in
Renal Disease equation. Patients from 11 phase 3
studies were included. Patients with a CrCl <30 ml/min
were excluded from TURQUOISE-III, TOPAZ-I, and
TOPAZ-II, and patients with a CrCl <60 ml/min were
excluded from TURQUOISE-I, TURQUOISE-II, PEARL-
II, PEARL-III, PEARL-VI, SAPPHIRE-I, and SAP-
PHIRE-II.
The study designs and primary outcomes are
described elsewhere.11–20 The studies were conducted
in accordance with the International Conference on
Harmonisation guidelines, applicable regulations, and
the principles of the Declaration of Helsinki; study
protocols were approved by independent ethics com-
mittees at each study site; and all patients provided
written informed consent.
Patient Population
Patients infected with HCV GT1 without cirrhosis or
with Child–Pugh A cirrhosis who had received $1
dose of OBV/PTV/r þ DSV  RBV were included in the
analysis. Data collected before January 1, 2016 were
included. In this analysis, patients were grouped ac-
cording to baseline eGFR and CKD stage (CKD5: #15
ml/min per 1.73 m2; CKD4: >15–30 ml/min per 1.73 m2;
CKD3: >30–60 ml/min per 1.73 m2; CKD2: >60–90 ml/
min per 1.73 m2; and CKD1 >90 ml/min per 1.73 m2).
One patient with CKD5 on hemodialysis received OBV/
PTV/r þ DSV þ RBV.
Study Medication
Patients with HCV GT1 infection without cirrhosis
received OBV/PTV/r (25/150/100 mg every day) and
DSV (250 mg twice a day) for 12 weeks; patients with
GT1a infection also received RBV. Patients with
compensated cirrhosis received OBV/PTV/r (25/150/100
mg every day) and DSV (250 mg twice a day) with RBV
for 12 or 24 weeks for GT1b and GT1a infection,
respectively. In the TURQUOISE-III trial, GT1b pa-
tients with cirrhosis did not receive RBV and were
treated for 12 weeks. RBV was dosed according to body
weight (1000 mg: <75 kg; 1200 mg: $75 kg) for pa-
tients with baseline CrCl $50 ml/min and was dose-
adjusted for patients with CrCl <50 ml/min.10 Patients
with CKD4 to 5 who required RBV received 200 mg every
day. Investigators in all studies could reduce, interrupt,
or resume RBV based on hemoglobin levels.
Virologic Response
Plasma HCV RNA levels were determined by a central
laboratory using the Roche COBAS TaqMan real-time
reverse-transcriptase polymerase chain reaction assay
v2.0 (lower limit of quantitation ¼ 25 IU/ml) (Roche,
Nutley, NJ) or Roche COBAS AmpliPrep/COBAS Taq-
Man HCV Test, v2.0 (lower limit of quantitation ¼ 15
IU/ml) (Roche).
SVR rates at posttreatment week 12 (SVR12; HCV
RNA less than lower limit of quantitation) were
calculated for all patients, including those who dis-
continued OBV/PTV/r þ DSV  RBV prematurely.
Safety
Data on all treatment-emergent AEs, as reported by the
study investigator, were collected from the start of
study drug administration until 30 days after the last
dose. AEs were assessed by study investigators for
relation to study drug and severity. Serious AEs were
collected from the time of signed consent until 30 days
after the last dose of OBV/PTV/r þ DSV  RBV. Clin-
ical laboratory chemistry and hematology tests were
assessed throughout each study. Renal-associated AEs
were defined by the Standardized Medical Dictionary
for Regulatory Activities (MedDRA version 18.1)
Queries Acute Renal Failure and Chronic Kidney Dis-
ease and the Custom MedDRA Query (version 18.1.3)
Designated Medical Event Acute Renal Failure. Mean
changes from baseline to end of treatment (EOT) of
serum creatinine (SCr) and eGFR were calculated to
assess changes in renal function.
Statistical Analyses
Efficacy and safety populations included all patients
who received at least 1 dose of OBV/PTV/r þ DSV 
RBV. Efficacy and safety analyses were performed for
CKD stages 1 to 5. Results for patients with CKD4 to 5
are not presented in full owing to low patient numbers.
Safety comparisons between treatment groups and CKD
subgroups were performed using Fisher exact test.
CLINICAL RESEARCH DE Bernstein et al.: OBV/PTV/r þ DSV  RBV in Patients With CKD
246 Kidney International Reports (2019) 4, 245–256
Analysis of covariance was used to assess changes in
renal function from baseline to EOT.
Changes in post-baseline eGFR at EOT in 255 pa-
tients in the placebo arms were compared with 769
patients in the OBV/PTV/r þ DSV þ RBV treatment
arms of the SAPPHIRE-I and -II trials. Changes in post-
baseline eGFR at EOT were assessed in 2663 patients
from 7 trials (SAPPHIRE-I, SAPPHIRE-II, TURQUOISE-
II, TOPAZ-II, PEARL-II, PEARL-III, PEARL-IV) in
which urinalysis was conducted at baseline and base-
line factors associated with a $10 ml/min per 1.73 m2
increase in eGFR at EOT were examined by stepwise
logistic regression.21
RESULTS
Baseline Patient Demographics and
Characteristics
A total of 3567 patients were included in the pooled
analysis; 29% (1033/3567) received OBV/PTV/r þ DSV
and 71% (2534/3567) received OBV/PTV/r þ DSV þ
RBV. Baseline characteristics are presented in Table 1.
Overall, 47% (1674/3567), 50% (1801/3567), and 3%
(92/3567) of patients had stage 1, 2, or 3 CKD,
respectively. Only 1% (22/3567) of patients had an
eGFR <50 ml/min per 1.73 m2 (data not shown).
Efficacy Outcomes
Among patients treated with OBV/PTV/r þ DSV
without RBV, SVR12 rates were high irrespective of
CKD stage (CKD1 97% [439/453]; CKD2 98% [536/547];
CKD3 97% [32/33]) or presence of cirrhosis (Figure 1a).
In patients with cirrhosis receiving OBV/PTV/r þ DSV
without RBV, SVR12 was 100% (62/62), including 61
patients with GT1b infection (Figure 1; Supplementary
Figure S1). High SVR12 rates were also achieved with
OBV/PTV/r þ DSV þ RBV. The SVR12 rate was 93%
(55/59) in patients with CKD3 and 96% in those with
CKD1 or CKD2 (1172/1221 and 1208/1254, respectively;
Figure 1b). RBV dose modification was required in 11%
(273/2534) of patients with CKD1 to 3; SVR rates were
not decreased among patients who had RBV dose
reduction (Supplementary Figure S2). SVR12 rates in
subgroups were high irrespective of CKD stage and did
not differ from the overall SVR12 rates (Figure 1). There
were no statistically significant differences among CKD
stages 1, 2, and 3.
Table 1. Baseline patient demographics and disease characteristics
Baseline characteristic
OBV/PTV/r D DSV OBV/PTV/r D DSV D RBV
Total
(N [ 3567)
CKD1
(n [ 453)
CKD2
(n [ 547)
CKD3
(n [ 33)
Subtotal
(n [ 1033)
CKD1
(n [ 1221)
CKD2
(n [ 1254)
CKD3
(n [ 59)
Subtotal
(n [ 2534)
Male sex, n (%) 242 (53) 261 (48) 10 (30) 513 (50) 825 (68) 704 (56) 30 (51) 1559 (62) 2072 (58)
Race, n (%)
White 406 (90) 497 (91) 32 (97) 935 (91) 1095 (90) 1156 (92) 52 (88) 2303 (91) 3238 (91)
Black 33 (7) 40 (7) 1 (3) 74 (7) 93 (8) 72 (6) 6 (10) 171 (7) 245 (7)
Othera 14 (3) 9 (2) 0 23 (2) 33 (3) 26 (2) 1 (2) 60 (2) 83 (2)
Hispanic/Latino ethnicity, n (%) 27 (6) 36 (7) 2 (6) 65 (6) 108 (9) 83 (7) 3 (5) 194 (8) 259 (7)
Age, yr, meanSD 48.712.7 54.510.2 61.49.9 – 49.610.9 54.79.4 59.34.8 – –
BMI, kg/m2, meanSD 26.54.7 26.34.3 27.95.2 – 26.64.9 26.74.3 27.94.3 – –
HCV subgenotype, n (%)b
GT1a 75 (17) 126 (23) 4 (12) 205 (20) 844 (69) 847 (68) 46 (78) 1737 (69) 1942 (54)
GT1b 378 (83) 421 (77) 29 (88) 828 (80) 376 (31) 405 (32) 13 (22) 794 (31) 1622 (45)
IL28B non-CC genotype, n (%) 367 (81) 422 (77) 28 (85) 817 (79) 970 (79) 947 (76) 39 (66) 1956 (77) 2773 (78)
HCV RNA $800 000 IU/ml, n (%) 327 (72) 428 (78) 26 (79) 781 (76) 964 (79) 1036 (83) 53 (90) 2053 (81) 2834 (79)
Fibrosis stage, n (%)c
F0–F1 298 (66) 331 (61) 13 (39) 642 (62) 650 (53) 664 (53) 28 (47) 1342 (53) 1984 (56)
F2 72 (16) 103 (19) 8 (24) 183 (18) 140 (11) 173 (14) 7 (12) 320 (13) 503 (14)
F3 60 (13) 81 (15) 3 (9) 144 (14) 113 (9) 142 (11) 5 (8) 260 (10) 404 (11)
F4 23 (5) 30 (5) 9 (27) 62 (6) 317 (26) 275 (22) 19 (32) 611 (24) 673 (19)
Treatment naive, n (%) 287 (63) 392 (72) 19 (58) 698 (68) 736 (60) 783 (62) 38 (64) 1557 (61) 2255 (63)
History of hypertension, n (%) 99 (22) 163 (30) 18 (55) 280 (27) 284 (23) 395 (31) 27 (46) 706 (28) 986 (28)
History of diabetes mellitus, n (%) 6 (1) 11 (2) 0 17 (2) 45 (4) 34 (3) 1 (2) 80 (3) 97 (3)
Albumin (g/l), meanSD 43.33.7 42.93.4 41.73.2 – 42.63.9 42.33.5 42.43.3 – –
Platelet count (109/l),
meanSD
217.360.5 220.665.3 205.255.8 – 209.872.7 212.368.0 196.866.4 – –
eGFR (ml/min per 1.73 m2),
mean  SD
105.514.7 79.07.5 53.26.8 – 107.014.0 78.87.7 52.76.9 – –
–, not applicable; BMI, body mass index; CKD, chronic kidney disease; DSV, dasabuvir; eGFR, estimated glomerular filtration rate; GT, genotype; HCV, hepatitis C virus; IL28B, interleukin
28B; OBV, ombitasvir; PTV/r; paritaprevir/ritonavir; RBV, ribavirin.
aData missing for 1 patient.
bNon-GT1a/b genotype in 3 patients.
cData missing for 3 patients.
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Safety Outcomes
AEs and Serious AEs
Patients with less severe renal dysfunction tended
overall to have fewer AEs, and patients treated with
RBV tended to have more AEs than those treated
without RBV. Of 3567 patients in this analysis, 2870
patients experienced at least 1 AE (80%; Table 2). AEs
were significantly associated with CKD stage (CKD1
77% [1285/1674], CKD2 84% [1505/1801], CKD3 87%
[80/92]; P < 0.001). The most common AEs were
fatigue, headache, and anemia (Table 2 [see
Supplementary Table S1 for AEs in$10% of patients]).
In patients treated with RBV, the frequency of anemia
reported as an AE was greater in patients with CKD3
than in those with CKD2 or CKD1 (25% [15/59] vs. 8%
[103/1254], and 4% [43/1221], respectively; P < 0.001).
Anemia was uncommon among patients who did not
receive RBV (CKD3 0% [0/33], CKD2 0.4% [2/547],
CKD1 0.2% [1/453]; P ¼ not significant). AEs leading to
treatment discontinuation were infrequent and did not
Figure 1. Sustained virologic response rates at posttreatment week 12 in patients treated with OBV/PTV/r þ DSV without RBV (a) or with RBV
(b) by CKD stage (CKD1: >90 ml/min per 1.73 m2; CKD2:>60–90 ml/min per 1.73 m2; CKD3:>30–60 ml/min per 1.73 m2). The percentage of patients
who achieved SVR12 is plotted with 95% confidence intervals. CKD, chronic kidney disease; DSV, dasabuvir; GT, genotype; OBV, ombitasvir;
PTV/r; paritaprevir/ritonavir; RBV, ribavirin; SVR12, sustained virologic response rates at posttreatment week 12.
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Table 2. Treatment-emergent adverse events and renal-associated adverse events by CKD stagea
AE, n (%)
OBV/PTV/r D DSV OBV/PTV/r D DSV D RBV
Overall
(N [ 3567)
No cirrhosis Cirrhosis No cirrhosis Cirrhosis
CKD1
(n [ 430)
CKD2
(n [ 517)
CKD3
(n [ 24)
CKD1
(n [ 23)
CKD2
(n [ 30)
CKD3
(n [ 9)
CKD1
(n [ 904)
CKD2
(n [ 979)
CKD3
(n [ 40)
CKD1
(n [ 317)
CKD2
(n [ 275)
CKD3
(n [ 19)
Any AE 274 (64) 367 (71) 17 (71) 18 (78) 20 (67) 9 (100) 722 (80) 871 (89) 37 (93) 271 (85) 247 (90) 17 (90) 2870 (80)
Serious AE 5 (1) 7 (1) 1 (4) – – 1 (11) 19 (2) 23 (2) 4 (10) 19 (6) 14 (5) 2 (11) 95 (3)
AEs leading to discontinuation of
study drug
2 (<1) 1 (<1) – – – – 3 (<1) 8 (<1) – 4 (1) 8 (3) 1 (5) 27 (1)
AEs leading to RBV dose reduction – 1 (<1) – – – – 56 (6) 96 (10) 17 (43) 34 (11) 43 (16) 6 (32) 253 (7)
Fatal AE – – – – – – – 1 (<1) – 1 (<1) – – 2 (<1)
Renal-associated AEs (SMQ/CMQ) 4 (1) 10 (2) – – – 1 (11) 9 (1) 15 (2) 3 (8) 4 (1) 9 (3) 1 (5) 56 (2)
AEs occurring in $15% of patients in any subgroup
Fatigue 88 (20) 121 (23) 5 (21) 6 (26) 6 (20) 1 (11) 269 (30) 351 (36) 14 (35) 98 (31) 112 (41) 13 (68) 1084 (30)
Headache 88 (20) 109 (21) 5 (21) 2 (9) 6 (20) 3 (33) 203 (22) 284 (29) 7 (18) 71 (22) 71 (26) 6 (32) 855 (24)
Nausea – – – – 4 (13) – 150 (17) 201 (21) 7 (18) 54 (17) 61 (22) 5 (26) 482 (14)
Pruritus 27 (6) 40 (8) 3 (13) 1 (4) 4 (13) 1 (11) 113 (13) 140 (14) 7 (18) 49 (15) 55 (20) 3 (16) 443 (12)
Insomnia – – – 3 (13) 3 (10) 1 (11) 117 (13) 160 (16) 8 (20) 45 (14) 45 (16) 5 (26) 387 (11)
Diarrhea – – – 4 (17) 7 (23) 1 (11) 75 (8) 107 (11) 7 (18) 41 (13) 39 (14) 5 (26) 286 (8)
Cough – – – – – – 63 (7) 69 (7) 7 (18) 29 (9) 27 (10) 1 (5) 196 (5)
Dizziness – – – 1 (4) 5 (17) – 48 (5) 80 (8) 4 (10) 18 (6) 22 (8) 2 (11) 180 (5)
Anemia 1 (<1) 2 (<1) – – – – 25 (3) 70 (7) 12 (30) 18 (6) 33 (12) 3 (16) 161 (5)
Decreased appetite – – – – – – 50 (6) 48 (5) 6 (15) – – – 104 (3)
Hemoglobin decrease – – – – – – 23 (3) 32 (3) 6 (15) 15 (5) 18 (7) 2 (11) 96 (3)
Rash – – – – – – – – – 28 (9) 36 (13) 5 (26) 69 (2)
UTI – – – – – – 18 (2) 25 (3) 6 (15) – – – 49 (1)
Abdominal pain, upper – – – 1 (4) 1 (3) 1 (11) – – – 21 (7) 12 (4) 4 (21) 40 (1)
Depression – – – – – – – – – 10 (3) 11 (4) 4 (21) 25 (<1)
Blood bilirubin increase – – – – – – – – – 8 (3) 13 (5) 3 (16) 24 (<1)
Abdominal pain – – – – – – – – – 10 (3) 4 (2) 3 (16) 17 (<1)
Myalgia – – – 4 (17) – – – – – – – – 4 (<1)
–, no AE; AE, adverse event; CKD, chronic kidney disease; CMQ, Custom MedDRA Query; DSV, dasabuvir; OBV, ombitasvir; PTV/r; paritaprevir/ritonavir; RBV, ribavirin; SMQ, Standardized MedDRA Query; UTI, urinary tract infection.
aCKD1: >90 ml/min per 1.73 m2; CKD2: >60–90 ml/min per 1.73 m2; CKD3: >30–60 ml/min per 1.73 m2.
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differ significantly by CKD stage. Few patients (n ¼ 20)
with severe renal impairment (CKD4) or ESRD (CKD5)
were included in this analysis, and none of these pa-
tients treated with OBV/PTV/r þ DSV  RBV dis-
continued study drug owing to an AE.
Few patients (3% [95/3567]) had serious AEs, which
were numerically more frequent in patients treated
with (3% [81/2534]) than without RBV (1% [14/1033];
Table 2). More patients with CKD3 who were treated
with RBV had serious AEs (10% [6/59]) when compared
with those with CKD1 (3%, 38/1221) or CKD2 (3% [37/
1254]; P ¼ 0.008), irrespective of cirrhosis status. Only
0.2% of patients (2/1040) treated with OBV/PTV/r þ
DSV had a serious AE that was considered possibly
related to DAA study drug; both had CKD3. In patients
treated with RBV, 0.5% of patients (13/2547) had
serious AEs possibly related to DAA study drug (CKD2,
8; CKD1, 5). The serious AEs included anemia, acute
kidney injury, and acute prerenal failure (each in 1
patient). Serious AEs are provided in Supplementary
Table S2.
AEs leading to RBV dose reduction occurred in 10%
of patients with CKD1 to 3 (252/2534) with a higher
proportion in patients with cirrhosis than without
cirrhosis (14% [83/611] vs. 9% [169/1923]; P < 0.001).
AEs leading to RBV dose reduction were more frequent
in patients with CKD3 than either CKD1 or 2 (CKD1:
7% [90/1221]; CKD2: 11% [139/1254]; CKD3: 39% [23/
59]; P < 0.001). RBV dose reductions were not associ-
ated with reduced SVR rates (Supplementary
Figure S2). Of 13 patients with CKD4 or 5, 9 (64%)
had AEs leading to RBV dose reductions; none had
cirrhosis.
None of the 20 patients with CKD4 or 5 discontinued
study drug owing to an AE. Four (19%) had serious
AEs (none of which were considered possibly related to
the study drug).
Three fatal AEs occurred in patients treated with
RBV. Two patients died of cancer (metastatic pancreatic
Figure 2. Mean change in hemoglobin from baseline to EOT by
CKD stage (CKD1: >90 ml/min per 1.73 m2; CKD2: >60–90 ml/min
per 1.73 m2; CKD3: >30–60 ml/min per 1.73 m2). Mean change from
baseline in hemoglobin is plotted with SD. CKD, chronic kidney
disease; DAA, direct-acting antiviral; DSV, dasabuvir; EOT, end of
treatment; Hgb, hemoglobin; OBV, ombitasvir; PTV/r, paritaprevir/
ritonavir; RBV, ribavirin. P values represent a comparison of the
3-DAA with the 3-DAA þ RBV regimen. ***, **, and * denote
P values statistically significant to 0.001, 0.001, and 0.05 levels,
respectively.
Table 3. Renal-associated adverse events by CKD stagea,b
AE, n
OBV/PTV/r D DSV OBV/PTV/r D DSV D RBV
CKD1 (n [ 453) CKD2 (n [ 547) CKD3 (n [ 33) CKD1 (n [ 1221) CKD2 (n [ 1254) CKD3 (n [ 59)
Decreased CrCl – 5 1 5 9 2
Proteinuria 1 – – 6 3 –
Hyponatremia 1 3 – 1 4 –
Hypocalcemia – 1 – – 3 –
Leukocyturia 1 – – 2 1 –
AKI – – – – 3 –
Renal failure – – – – 1 2
Blood sodium decrease – 1 – – 1 –
Encephalopathy – – – – 2 –
Blood potassium increase – – – – 1 –
Blood urea increase – – – 1 – –
Hyperphosphatemia – – – – 1 –
Hypoalbuminemia – – – 1 – –
Metabolic acidosis – – – – 1 –
Pericarditis – 1 – – – –
RBC urine positive 1 – – – – –
–, no AE; AE, adverse event; AKI, acute kidney injury; CKD, chronic kidney disease; CrCl, creatinine clearance; DSV, dasabuvir; OBV, ombitasvir; PTV/r; paritaprevir/ritonavir; RBC, red
blood cell; RBV, ribavirin.
aData in the table represent all reported AEs; 1 patient may have had >1 AE.
bCKD1: >90 ml/min per 1.73 m2; CKD2: >60–90 ml/min per 1.73 m2; CKD3: >30–60 ml/min per 1.73 m2.
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cancer in a patient with CKD1; non–small-cell lung
cancer in a CKD2 patient), and 1 patient with CKD5
died of left ventricular dysfunction.
Among patients who received RBV, hemoglobin
decreases to <10 g/dl or $2 g/dl from baseline to EOT
occurred in 49% (593/1220), 61% (764/1250), and 78%
(45/58) of patients with CKD1, CKD2, and CKD3,
respectively. Fewer patients (2% [22/1032]) who did
not receive RBV had comparable hemoglobin re-
ductions. Recipients of RBV had significantly greater
hemoglobin reductions (P < 0.001 vs. recipients of 3-
DAA without RBV). Mean hemoglobin reductions
were significantly greater in patients with CKD1 or 2
versus CKD3: OBV/PTV/r þ DSV, P ¼ 0.025; OBV/
PTV/r þ DSV þ RBV, P < 0.001; Figure 2).
Renal-Associated AEs
Renal-associated AEs were infrequent, with 67 events
occurring in 2% (56/3567) of patients. The frequency
of renal-associated AEs increased with decreasing renal
function (CKD1: 17/1674 [1%]; CKD2: 34/1801 [2%];
CKD3: 5/92 [5%]; P ¼ 0.001; Table 2). Renal-associated
AEs in RBV recipients were reported in 1% (13/1221),
2% (24/1254), and 7% (4/59) of patients with CKD1, 2,
and 3, respectively (P ¼ 0.002). Among patients treated
without RBV, the incidence was 1% (4/453), 2% (10/
547), and 3% (1/33), respectively (P ¼ not significant;
Table 2). Most renal-associated AEs were of mild-to-
moderate intensity, with 7 patients (0.2%) experi-
encing severe events. The most common
renal-associated AEs were decreased CrCl (33% [22/
67]), proteinuria (15% [10/67]), and hyponatremia
(13% [9/67]; Table 3). In total, 29 (52%) patients had
renal-associated AEs (34 AEs in total) that were
considered by the study investigator to be possibly
related to either OBV/PTV/r þ DSV or RBV. Of 20
patients with CKD4 or 5, 1 recipient (CKD4) of RBV
experienced 2 renal-associated AEs (elevated SCr and
blood urea nitrogen) during treatment. Two patients
discontinued study drug treatment because of renal-
associated AEs. Ninety-three percent of renal-associated
AEs resolved during or after study drug treatment.
Effect of Treatment on Renal Function
We observed 2 distinct patterns of changes in kidney
function from baseline to EOT among patients with
CKD1, CKD2, and CKD3. Mean eGFR decreased among
patients with CKD1 but increased among patients
with CKD2 to 3 (Figure 3a). Similarly, mean SCr values
increased among patients with CKD1 and decreased
among patients with CKD2 or 3 (Figure 3b). Impor-
tantly, the largest gain in eGFR and decrease in SCr
occurred in patients with the lowest baseline eGFR
(CKD3). Mean eGFR increased from baseline to EOT in
recipients of RBV with CKD2 (1.55 ml/min per 1.73
m2) or CKD3 (5.85 ml/min per 1.73 m2) at baseline and
decreased in patients with CKD1 (–4.95 ml/min per
1.73 m2; Figure 3a). Similarly, mean SCr decreased
from baseline to EOT with OBV/PTV/r þ DSV  RBV
in patients with CKD2 (–0.50 mmol/L) or CKD3 (–5.95
mmol/L), whereas it increased in patients with CKD1
(3.25 mmol/L; Figure 3b). Given that the risk of CKD is
higher in patients with cirrhosis,4 we assessed the
impact of cirrhosis on renal function (Figure 4).
Among patients without cirrhosis with CKD3 at
baseline, a mean increase in eGFR of 4.5 ml/min per
1.73m2 and 6.9 ml/min per 1.73 m2 was observed in
patients treated with or without RBV, respectively. In
patients with cirrhosis with CKD3 at baseline, a mean
increase in eGFR of 8.0 ml/min per 1.73 m2 and 3.6
ml/min per 1.73 m2 was observed in patients treated
with or without RBV, respectively (Figure 4). By
contrast, the largest mean decreases in eGFR were
observed in patients with cirrhosis with CKD1. No
substantial change was reported in eGFR in patients
with CKD4 (0.9 ml/min per 1.73 m2) or CKD5 (–0.4 ml/
min per 1.73 m2) treated with or without RBV.
Figure 3. Mean change in eGFR (a) and serum creatinine (b) from
baseline to end of treatment by CKD stage (CKD1: >90 ml/min per
1.73 m2; CKD2: >60–90 ml/min per 1.73 m2; CKD3: >30–60 ml/min per
1.73 m2). All patients with CKD1 to 3 across 11 clinical trials. Data on
eGFR and serum creatinine were missing for 1 patient in the CKD3
group treated with OBV/PTV/r þ DSV þ RBV. CKD, chronic kidney
disease; DSV, dasabuvir; eGFR, estimated glomerular filtration rate;
OBV, ombitasvir; PTV/r, paritaprevir/ritonavir; RBV, ribavirin.
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Furthermore, regardless of baseline eGFR, no dif-
ference was observed in the proportion of patients with
either a decrease (Figure 5a) or increase (Figure 5b) in
eGFR by $10 ml/min per 1.73 m2 in the placebo (n ¼
255) and OBV/PTV/r þ DSV þ RBV (n ¼ 769) arms of
the SAPPHIRE-I and -II trials or the OBV/PTV/r þ DSV
 RBV (n ¼ 2663) arms of 7 clinical trials in which
baseline urinalysis was performed.21
Baseline Factors Associated With eGFR
Improvement
Stepwise logistic regression analysis was performed to
identify baseline factors associated with $10 ml/min
per 1.73 m2 improvement in eGFR in 7 clinical trials
with baseline urinalysis data. Overall, 18% of patients
(486/2663) experienced $10 ml/min per 1.73 m2 in-
crease in eGFR at EOT (Figure 5b). Baseline factors
significantly associated with this increase were body
mass index (P < 0.001), nonblack race (P ¼ 0.021),
proteinuria (P < 0.001), and diabetes (P ¼ 0.023;
Table 4). When the analysis was done on the placebo
group in SAPPHIRE-I and -II, changes in eGFR were
not associated with any baseline factors.21
Figure 5. Post-baseline decrease (a) and increase (b) in eGFR
by $10 ml/min per 1.73 m2 at EOT. Patients were from 7 clinical trials
(SAPPHIRE-I, SAPPHIRE-II, TURQUOISE-II, TOPAZ-II, PEARL-II,
PEARL-III, PEARL-IV). DSV, dasabuvir; eGFR, estimated glomerular
filtration rate; EOT, end of treatment; OBV, ombitasvir; PTV/r, par-
itaprevir/ritonavir; RBV, ribavirin.
Table 4. Baseline factors associated with improvement in eGFRa
Variable
‡10 ml/min per 1.73 m2 eGFR
improvement
OR 95% CI P value
Baseline proteinuria (positive vs. negative) 1.65 1.32–2.05 <0.001
Baseline BMI 0.95 0.93–0.97 <0.001
Race (black vs. nonblack) 0.60 0.38–0.92 0.021
History of diabetes (yes vs. no) 1.51 1.06–2.16 0.023
BMI, body mass index; CI, confidence interval; eGFR, estimated glomerular filtration
rate; OR, odds ratio.
aBaseline characteristics that were evaluated by linear regression analysis: urine blood
(positive or negative), urine protein (positive or negative), fibrosis score (F0–1, F2, F3, F4),
BMI (continuous, kg/m2), age (continuous, years), sex (male or female), race (black or
nonblack), history of hypertension (yes or no), history of diabetes (yes or no), baseline
hepatitis C virus RNA (continuous, log10 IU/ml).
Figure 4. Mean change in eGFR (a) and serum creatinine (b) from
baseline to end of treatment according to CKD stage (CKD1: >90 ml/
min per 1.73 m2; CKD2: >60–90 ml/min per 1.73 m2; CKD3: >30–60 ml/
min per 1.73 m2) and presence of cirrhosis. All patients with CKD1 to
3 across 11 clinical trials. Data on eGFR and serum creatinine were
missing for 1 patient in the CKD3 group treated with OBV/PTV/r þ
DSV þ RBV. P values represent a comparison with CKD1. ***, **,
and * denote P values statistically significant to 0.001, 0.001, and 0.05
levels, respectively. CKD, chronic kidney disease; DSV, dasabuvir;
eGFR, estimated glomerular filtration rate; OBV, ombitasvir; PTV/r,
paritaprevir/ritonavir; RBV, ribavirin.
CLINICAL RESEARCH DE Bernstein et al.: OBV/PTV/r þ DSV  RBV in Patients With CKD
252 Kidney International Reports (2019) 4, 245–256
CONCLUSION
Given that HCV infection is implicated in the develop-
ment and progression of CKD, it is important to identify
and treat HCV in patients with CKD. However, given
that patients with CKD were generally excluded from
registration trials, more data are needed to confirm the
safety and efficacy of DAAs in patients with CKD.22
In the present analysis, the safety and efficacy of
OBV/PTV/r þ DSV  RBV were assessed in 3567 GT1-
infected patients with CKD stages 1 to 3 across 11 phase
3 studies. It should be noted that some patients
received regimens not presently recommended in
product labeling. For example, some GT1b-infected
patients with cirrhosis received OBV/PTV/r þ DSV
with RBV for 12 weeks, whereas European Union and
US product labeling recommends OBV/PTV/r þ DSV
alone for all GT1b-infected patients, including those
with compensated cirrhosis. Similarly, the approved
regimens for GT1a-infected patients are OBV/PTV/r þ
DSV þ RBV for 12 weeks in patients without cirrhosis
and 24 weeks in patients with compensated cirrhosis.
However, this analysis includes GT1a-infected patients
who received OBV/PTV/r þ DSV without RBV, in
whom the SVR12 rate was 90%. Among patients who
received the label-recommended regimen based on
HCV subtype, SVR rates across CKD strata were similar
to those reported in the registration trials. Regardless of
GT1 subgroup or receipt of RBV, high overall SVR rates
(93%–98%) were achieved and were similar across
CKD stages. In addition, SVR rates were consistently
high in subgroups defined by cirrhosis status, irre-
spective of CKD stage.
OBV/PTV/r þ DSV  RBV was generally well
tolerated irrespective of CKD stage. Relatively few pa-
tients (3%) had a serious AE, and AEs leading to
treatment discontinuation occurred in <1% of patients
and did not differ by CKD stage.
The safety profile of OBV/PTV/r  RBV in patients
with CKD3 was largely similar to that in patients with
CKD1 or CKD2. However, serious AEs and renal-
associated AEs were more common in patients with
CKD3 than in patients with CKD1/2. Many were
considered unrelated to DAA therapy, suggesting that
this difference reflects the greater underlying
morbidity in patients with CKD3.
No worsening of eGFR was observed with OBV/PTV/
r þ DSV þ RBV, regardless of baseline CKD stage in
placebo-controlled trials (SAPPHIRE-I/II). eGFR
increased and SCr decreased from baseline to EOT in
patients with CKD2 or 3 treated with OBV/PTV/r þ
DSV  RBV, suggesting that this regimen does not
affect renal function in patients with moderate CKD.
Although these parameters improved in patients with
CKD3, these data are insufficient to conclude that renal
function improves in patients with moderate renal
impairment. A large, community-based study showed a
correlation between decreasing eGFR and increasing
risk of death, cardiovascular events, and hospitaliza-
tion23; however, it is unknown whether improvements
in eGFR observed in this analysis persist after treat-
ment and translate into improved clinical outcomes.
Several factors (positive baseline proteinuria, lower
baseline body mass index, nonblack race, and a history
of diabetes) were associated with improved eGFR in the
subanalysis of baseline urinalysis data and may be used
to identify patients likely to benefit from treatment.
Studies with prolonged observation periods are needed
to assess whether eradication of HCV affects the pro-
gression of kidney disease and improves survival in
patients with renal impairment.
The results of this study are supported by a German
real-world study of more than 1000 GT1- or GT4-
infected patients with or without renal impairment
who received OBV/PTV/r  DSV  RBV.24 The SVR12
rate among patients with moderate-to-severe renal
impairment (eGFR <60 ml/min per 1.73 m2) was 100%
(34/34), and the safety profile among patients with any
degree of renal impairment (eGFR #90 ml/min per 1.73
m2; n ¼ 326) was similar to the overall population.24 In
addition, no clinically relevant changes in eGFR from
baseline to EOT were observed for the overall popu-
lation or for any CKD subgroup.24
These results contrast with those obtained with
sofosbuvir-based regimens. Sofosbuvir, a nucleoside
analog HCV polymerase inhibitor, and its principal
metabolite GS-331007 are renally excreted.25 Sofosbu-
vir and GS-331007 exposures are 171% and 451%
higher, respectively, in patients with an eGFR of <30
ml/min per 1.73 m2 than in patients with normal renal
function.26 The incidence of serious AEs and wors-
ening renal function in patients with eGFR#45 ml/min
per 1.73 m2 (moderate renal impairment or worse) was
3.5-fold higher than that in patients with eGFR >45 ml/
min per 1.73 m2 in a cohort of 1789 sofosbuvir re-
cipients.25 Similarly, patients with eGFR <60 ml/min
per 1.73 m2 were more likely to experience worsening
of eGFR than patients with normal renal function after
controlling for age, fibrosis stage, and treatment dura-
tion in a retrospective study of recipients of ledipasvir/
sofosbuvir.27 In another report, sofosbuvir plus sime-
previr were well tolerated in patients with severe CKD
or ESRD.28 It is not known if sofosbuvir or its metab-
olite have a pathogenic effect; however, guidelines do
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not recommend use of sofosbuvir in patients with se-
vere renal impairment (eGFR <30 ml/min per 1.73 m2)
or ESRD requiring hemodialysis.8,9
Grazoprevir (NS3 protease inhibitor) and elbasvir
(NS5A inhibitor) are hepatically metabolized; thus,
dose adjustments are unnecessary in patients with
renal impairment.29 This regimen was well tolerated,
with an SVR12 rate of 94% to 99% in GT1-infected
patients with CKD4 or 5, including hemodialysis pa-
tients.30 In addition, the pan-genotypic regimen of
glecaprevir (NS3 protease inhibitor) and pibrentasvir
(NS5A inhibitor) is approved for patients with any
degree of renal impairment without dosage adjust-
ment31; this regimen achieved an SVR12 rate of 98% in
patients infected with GT1 to 6 with CKD4 or 5,
including patients requiring hemodialysis, and was
well tolerated.32 Separate integrated analyses of grazo-
previr plus elbasvir and glecaprevir plus pibrentasvir
showed no worsening of eGFR from baseline with
either regimen in patients with renal impairment.33,34
Few patients with CKD4 or 5 were included in this
analysis; however, the safety profile of OBV/PTV/r þ
DSV  RBV in these patients was generally similar to
that in patients with CKD1 to 3. In RUBY-I, OBV/PTV/
r þ DSV  RBV achieved an SVR12 rate (by intention-
to-treat analysis) of 90% in the initial cohort of GT1-
infected patients without cirrhosis with CKD4 or 5.11
The safety profile was generally similar to that in pa-
tients with normal renal function, with the exception
of a higher incidence of RBV treatment interruptions
therapy owing to anemia,11 similar to the current
analysis. SVR12 rates of 96% (46/48; 95% in GT1a [35/
37] and 100% in GT1b [11/11] patients) were achieved
in a second cohort of patients with CKD4 or 5 with or
without compensated cirrhosis (including treatment-
experienced patients). Most AEs were mild or moder-
ate in severity, and only 1 patient discontinued treat-
ment due to DAA-related serious AE (diarrhea).35
Similarly, real-world studies of OBV/PTV/r  DSV 
RBV in GT1- and GT4-infected patients with CKD4 or
5, including patients who require hemodialysis, have
shown SVR12 rates >95% and good tolerability.36–38
In this study, the frequency of serious AEs was
higher in the small group of patients with CKD4 or 5
than in patients with CKD1 to 3. This was also observed
in an integrated analysis of more than 2000 patients
with GT1 to 6 treated with glecaprevir and pibrentas-
vir, with an increased rate of serious AEs, as well as a
higher frequency of the AE of pruritus, among patients
with CKD4 or 5 (n ¼ 103).34
RBV is eliminated by renal excretion; thus, exposure
to RBV and the risk of dose-related AEs is increased in
patients with renal impairment. The incidence of renal-
associated AEs was generally low across CKD groups,
but was higher in patients treated with RBV. For
example, anemia occurred in 25% of ribavirin re-
cipients with CKD3, compared with 4% to 8% in those
with CKD1 or 2. Similarly, AEs resulting in RBV dose
reductions occurred in 39% of patients with CKD3 and
7% to 11% of those with CKD1 or 2. The collective
results of the present study and RUBY-I suggest dose
adjustments do not completely abrogate the risk of
RBV-associated toxicity. Thus, dose reductions and
frequent hematologic monitoring are warranted in pa-
tients with CKD $3 who require RBV. It is noteworthy
that SVR12 rates were not affected by RBV dose re-
ductions in any CKD stratum.
RBV-Free Regimens Are Preferred in Patients
With ESRD
In the exploratory RUBY-II study, in which treatment-
naive patients infected with GT1a (n ¼ 13) or GT4 (n ¼
4) without cirrhosis and with CKD4 or 5 received OBV/
PTV/r  DSV, the SVR12 rate was 100% (excluding 1
GT4-infected patient who withdrew from the study at
week 2 for renal transplantation). The RBV-free
regimen was well tolerated; no serious AEs were
related to the study drugs. These results suggest that
RBV may not be required in some GT1a and GT4 pa-
tients; however, larger trials are needed to confirm
these results.39
In conclusion, in this pooled analysis of 3567 GT1-
infected patients with renal impairment across 11
phase 3 studies treated with OBV/PTV/r þ DSV  RBV
for 12 or 24 weeks achieved high SVR rates indepen-
dent of baseline renal function. Treatment was well
tolerated across CKD groups, with low rates of renal-
associated AEs and discontinuations. A gain in eGFR
at the EOT was observed in patients with CKD2 or 3.
Several baseline characteristics were associated with
improved eGFR in a subset of 2663 patients who had
urinalysis at baseline; however, the long-term benefit
and durability of this improvement are yet to be
determined. Patients treated with RBV were at higher
risk of AEs; consequently, RBV doses should be
reduced in and patients should be closely monitored
for RBV-associated anemia during treatment with OBV/
PTV/r þ DSV þ RBV.
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